The COVID-19 pandemic was influential in accelerating the development and evolution of mRNA liquid nanoparticle (mRNA-LNP) technology. The evolution of vaccine technology has increased global demand for manufacturing capacity, allowing governments to prepare for hypothetical outbreaks such as Disease X. Development is not just limited to infectious disease vaccines. Nucleic acid therapeutics can be designed and formulated to silence, express, and edit specific genes, providing a flexible and powerful approach to preventing and treating diseases.
As we step into the next era for mRNA-LNP therapeutics, we will look back on what we learned from our experiences in developing mRNA-LNP research and manufacturing processes in the field. We will also assess the mRNA-LNP workflow in its current form.